The carcinogenicity of traditional Chinese medicine components is once again clear, which has been banned in most countries. The domestic attitude is anodyne. Moreover, this carcinogenic ratio is extremely high, and the genetic mutation caused by it is difficult to repair! More importantly, as long as you are taking Chinese medicine, you may eat it! The following is a list of prohibited drugs: Aristolochia: Aristolochia macrophylla, Aristolochia australis, Aristolochia guannan, Aristolochia trifoliata, Aristolochia macrophylla, Aristolochia crenata, Aristolochia cucurbitae, Aristolochia tetrandra, Aristolochia Tongcheng, Aristolochia hainanensis, Aristolochia tetrandra, Aristolochia tetrandra, and Aristolochia tetrandra tetrandra.
Before 15, aristolochic acid was listed as a carcinogen of 1. Including Europe, the United States, China, Taiwan Province Province and Hongkong, have banned the use of Chinese medicines containing aristolochic acid, but many families in Chinese mainland have proprietary Chinese medicines containing aristolochic acid.
A heavy paper on aristolochic acid appeared on the cover of the authoritative medical journal Science Translation Medicine. This study shows that toxic herbs containing aristolochic acid are one of the important causes of liver cancer in Asia. In other words, Chinese medicine containing aristolochic acid is one of the chief culprits of liver cancer in China.
Aristolochic acid is a chemical component in some Chinese herbal medicines, which can induce very special mutation in cells. Now, as long as we pass the genetic test, we can immediately judge whether this tumor has anything to do with aristolochic acid. Researchers have done genetic testing on liver cancer samples from all over Asia, and found that 47% of liver cancer samples in Chinese mainland, 78% of liver cancer samples in Taiwan Province Province and 56% of liver cancer samples in Southeast Asia are obviously related to aristolochic acid-induced cell mutation.
There are more than 30 kinds of Chinese herbal medicines containing aristolochic acid. As early as September of 20 13, Caijing magazine published an article pointing out that aristolochic acid, which has been proved to be a strong carcinogen, has been banned in Europe, the United States, Taiwan Province Province of China and Hongkong, China, but it is still managed as a prescription drug in Chinese mainland.
In the past four years, many families have stocked Chinese patent medicines containing aristolochic acid for treating colds and coughs. The conclusion of this new study not only makes the reliability of Chinese medicine questioned again, but also points out that people's health has been threatened for a long time.
Aristolochic acid residue
In fact, in early August of 20 13, Professor Zheng and others of Singapore National Cancer Center published a paper in Science Translational Medicine, saying that Chinese herbal medicine containing aristolochic acid can cause gene mutation in kidney, which in turn leads to renal cancer. The researchers also pointed out that aristolochic acid is likely to be related to liver cancer.
At the end of August of that year, the British Medicines and Healthcare Products Administration (MHRA) issued a warning in official website, reminding people to carefully choose Chinese medicines that are not officially registered in the UK because they contain high levels of harmful toxins.
From 65438 to 0997, drugs containing aristolochic acid were prescribed in Britain, and then they were completely banned. But three years ago, according to the BBC, a 48-year-old female doctor in China sold drugs containing aristolochic acid to a British patient, which led to renal failure and cancer. The judge believes that this case shows that there is a lack of management of the safety of traditional Chinese medicine in Britain.
In 2004, the European Union issued the Directive on the Registration Procedure of Traditional Botanical Medicines, requiring that proprietary Chinese medicines sold in the EU market must be registered on April 30th, 201year, otherwise they are not allowed to be sold. Although the regulatory documents applied for are relatively simplified, and the requirements for registration of traditional Chinese medicine are completely equivalent to those of chemical drugs, so far, no enterprise in China has registered in the European Union. Li Chunxuan, a partner of Beijing Zhongyu Weisheng Intellectual Property Agency Co., Ltd., believes that this is part of the reason why the British Drug Administration banned proprietary Chinese medicines.
The latest research proves that aristolochic acid has strong carcinogenicity, but Chinese herbal medicines containing aristolochic acid are still sold in Chinese mainland.